Wiley (NYSE: WLY), a provider of content and research intelligence, announced on Tuesday that it has launched Advanced Immunology, a new open access journal focused on basic, clinical and translational immunology, as part of the continued expansion of its Advanced Portfolio of scientific publications.
The journal is now open for submissions and aims to connect research spanning fundamental immune mechanisms, emerging technologies and clinical applications to advance understanding of the immune system in health and disease. Its launch follows the recent introduction of Advanced Oncology and Advanced Brain, taking Wiley's Advanced Portfolio to more than 30 titles.
Advanced Immunology is led by editor-in-chief Jay H. Bream, PhD, a professor at the Johns Hopkins Bloomberg School of Public Health with editorial experience at Frontiers in Immunology and Genes and Immunity. The journal is supported by an international editorial advisory board representing a broad range of immunology research.
Aurinia initiates PRESERVE Phase 4 study of LUPKYNIS combination therapy in lupus nephritis
Anixa Biosciences advances ovarian cancer CAR-T trial to highest dose level
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
Brii Bio reports Phase 2 end-of-treatment data in chronic hepatitis B
Nona Biosciences names new chief operating officer
SK bioscience to lead Gates Foundation-funded ROTOR project
Arcturus Therapeutics and Thermo Fisher enter strategic collaboration on ARCT-032 development
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
Neurocrine Biosciences initiates crinecerfont Phase 2 study in young children with classic CAH
Abbisko Therapeutics and AstraZeneca collaborate to conduct combination clinical trial for NSCLC
Ipsen to acquire Memo Therapeutics to expand rare disease portfolio
Eurobio Scientific completes acquisition of CareDx's transplant lab products business